In This Section


Abstract Submission DeadlineWednesday, July 7, 2021, 11:59 a.m. EDT
Late-Breaking Abstract Submission DeadlineWednesday, August 25, 2021, 11:59 a.m. EDT

Individuals interested in submitting an abstract for presentation during the conference must do so through the AACR Online Submission System below.

Log onto myAACR. If you are an AACR member, please use your AACR username and password. If you have forgotten either, you can look it up on the website by entering your Member ID. For non-AACR members, you will need to create a free myAACR account to submit your abstract.

Note: This is free and the account is not for membership to the AACR, only to submit your abstract.

Authors who submit abstracts confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the 2021 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference. Each abstract should contain: (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions.

Please be sure to carefully check your abstract for content errors, spelling, names, etc. before submitting. The AACR does not proofread for or correct spelling, typographical, grammatical, or scientific errors, nor can changes be made once the abstract is submitted. If you have any questions or experience any problems, please contact AACR Abstract Support at [email protected].

Encore abstract submission guidelines 

The 2021 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference will be accepting encore clinical trials presentations, including trials in progress (TiP). Authors must supply information regarding the original presentation, indicating the name of the meeting and publication number at the time of submission. The first author will be responsible for obtaining, and, upon request, showing proof that written permission has been obtained from the copyright holder of the original abstract publication(s). Encore TiP abstract submissions will be accepted for poster presentation only.  

Encore submissions must: 


Angiogenesis and antiangiogenesis agents

Animal models

Apoptosis, necrosis, and autophagy


Biomarkers Cancer stem cells

Cell cycle regulators

Cellular responses to therapy



Clinical trials

DNA repair and modulation

Drug delivery

Drug design

Drug metabolism, transport, and biodistribution

Drug resistance and modifiers

Drug screening


Epigenetic regulation of tumor immunity

Epigenetic targets

Gene therapies

Genomics, proteomics, and target discovery

Heat shock proteins

Hormonal agents and therapy


Immune checkpoints

Immune mechanisms invoked by radiation therapy

Immune modulators

Immune monitoring/clinical correlates

Immune response to therapies

In vitro and in vivo models for targets

MAPK pathways


Metastasis and invasion

Molecular classification of tumors

Monoclonal antibodies


Natural products

New molecular targets

Novel assay technology

Pediatric-early drug development

Pharmacogenetics, pharmacogenomics, and therapeutic response

Pharmacokinetics and pharmacodynamics

Protein-protein interaction


RNA and RNA-based technologies and therapies

Signal transduction modulators

Target identification and validation

Therapeutic agents: biological

Therapeutic agents: other

Therapeutic agents: small-molecule kinase inhibitors

Topoisomerase inhibitors


Tubulin-interacting agents

Tumor immunology targets

Tumor microenvironment

Tumor suppressors



Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters. Presenting authors who are selected for a proffered talk will receive an e-mailed request to disclose their financial relationships.  For more information on financial relationships, visit


All individuals listed as ABSTRACT PRESENTERS will be notified of acceptance or rejection by email approximately four weeks after the abstract submission deadline. Notices and instructions will be sent to the email address provided at the time of abstract submission. If an abstract is not selected for presentation, the presenter may request a full refund of the registration fee by contacting the AACR Meetings Department at [email protected].


Accepted abstracts will be published as an online-only Proceedings supplement to an AACR journal after the completion of the meeting. Abstracts selected for presentation during the conference will be posted to the virtual conference platform. Every effort will be made to reproduce the content of the abstracts as submitted, except in certain circumstances where changes may be made to comply with AACR style. Abstract titles and authors will be posted on the AACR website on September 30 (only titles and authors; no data will be posted online before the conference). Details on the length and format of the presentations will be provided to individuals noted as ABSTRACT PRESENTERS of accepted abstracts. For programs that include short talks selected from the abstract submissions, instructions will be sent to the ABSTRACT PRESENTERS with the date, time, and format for those presentations.


Individuals planning on presenting an abstract at this conference are encouraged to register as early as possible. If an abstract is not accepted for presentation at the conference, the presenter may request a full refund of the registration fee. For additional information, please visit the registration page.


Once an abstract has been submitted, it may be withdrawn only by written request from the ABSTRACT PRESENTER. The request may be emailed to [email protected] and must be received by September 27.